

Geralyn M Messerlian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6912513/publications.pdf>

Version: 2024-02-01

104
papers

6,924
citations

117453

34
h-index

58464

82
g-index

107
all docs

107
docs citations

107
times ranked

5707
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between sleep disordered breathing in early pregnancy and glucose metabolism. <i>Sleep</i> , 2022, 45, .	0.6	12
2	PAPP-A Results Cannot Be Used to Accurately Estimate Gestational Age. <i>Journal of Applied Laboratory Medicine</i> , 2022, 7, 1000-1002.	0.6	1
3	Human chorionic gonadotropin-mediated modulation of pregnancy-compatible peripheral blood natural killer cells in frozen embryo transfer cycles. <i>American Journal of Reproductive Immunology</i> , 2021, 85, e13324.	1.2	3
4	Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors. <i>Tumor Biology</i> , 2021, 43, 355-365.	0.8	4
5	Serum Decorin and Biglycan as Potential Biomarkers to Predict PPROM in Early Gestation. <i>Reproductive Sciences</i> , 2020, 27, 1620-1626.	1.1	4
6	Adjusting antimüllerian hormone levels for age and body mass index improves detection of polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2020, 113, 876-884.e2.	0.5	7
7	AMH is Higher Across the Menstrual Cycle in Early Postmenarchal Girls than in Ovulatory Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1762-e1771.	1.8	7
8	Maternal BMI, Peripheral Deiodinase Activity, and Plasma Glucose: Relationships Between White Women in the HAPO Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2593-2600.	1.8	12
9	Serum Decorin and Biglycan as Potential Biomarkers to Predict PPROM in Early Gestation. <i>Reproductive Sciences</i> , 2019, , 193371911983179.	1.1	6
10	Fewer women aged 35 and older choose serum screening for Down syndrome: Impact and implications. <i>Journal of Medical Screening</i> , 2019, 26, 59-66.	1.1	1
11	Relaxin-2 connecting peptide (pro-RLX2) levels in second trimester serum samples to predict preeclampsia. <i>Pregnancy Hypertension</i> , 2018, 11, 124-128.	0.6	6
12	Snoring and markers of fetal and placental wellbeing. <i>Clinica Chimica Acta</i> , 2018, 485, 139-143.	0.5	9
13	Comparison of Inhibin Alpha Subunit and Antimüllerian Hormone Immunoreactivity in Granulosa Cell and Mucinous Ovarian Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 71-77.	0.6	4
14	The clinical utility of DNA-based screening for fetal aneuploidy by primary obstetrical care providers in the general pregnancy population. <i>Genetics in Medicine</i> , 2017, 19, 778-786.	1.1	36
15	Nuchal translucency measurement in the era of prenatal screening for aneuploidy using cell free (cf)DNA. <i>Prenatal Diagnosis</i> , 2017, 37, 303-305.	1.1	7
16	Assessment of serum HE4 levels throughout the normal menstrual cycle. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 53.e1-53.e9.	0.7	6
17	Correlation between follicular fluid levels of sRAGE and vitamin D in women with PCOS. <i>Journal of Assisted Reproduction and Genetics</i> , 2017, 34, 1507-1513.	1.2	25
18	Measuring maternal serum screening markers for Down syndrome in plasma collected for cell-free DNA testing. <i>Journal of Medical Screening</i> , 2017, 24, 113-119.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Use of antimüllerian hormone to predict the menopausal transition in HIV-infected women. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 46.e1-46.e11.	0.7	21
20	Where have all the trisomies gone?. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 583-587.e1.	0.7	13
21	Cut-off levels for hyperandrogenemia among Samoan women: An improved methodology for deriving normative data in an obese population. <i>Clinical Biochemistry</i> , 2016, 49, 782-786.	0.8	2
22	Levels of antimüllerian hormone in serum during the normal menstrual cycle. <i>Fertility and Sterility</i> , 2016, 105, 208-213.e1.	0.5	60
23	Free Thyroxine During Early Pregnancy and Risk for Gestational Diabetes. <i>PLoS ONE</i> , 2016, 11, e0149065.	1.1	33
24	Prenatal serum screening markers may not require adjustment in former smokers. <i>Prenatal Diagnosis</i> , 2015, 35, 1371-1373.	1.1	0
25	Placenta-secreted circulating markers in pregnant women with obstructive sleep apnea. <i>Journal of Perinatal Medicine</i> , 2015, 43, 81-87.	0.6	45
26	Impact of $CD4+$ Lymphocytes and HIV Infection on Anti-müllerian Hormone Levels in a Large Cohort of HIV-infected and HIV-uninfected Women. <i>American Journal of Reproductive Immunology</i> , 2015, 73, 273-284.	1.2	36
27	An Inverse Relationship Between Weight and Free Thyroxine During Early Gestation Among Women Treated for Hypothyroidism. <i>Thyroid</i> , 2015, 25, 949-953.	2.4	8
28	Obstructive sleep apnea is associated with alterations in markers of fetoplacental wellbeing. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2015, 28, 262-266.	0.7	25
29	Evaluation of Patient Education Materials: The Example of Circulating cell free DNA Testing for Aneuploidy. <i>Journal of Genetic Counseling</i> , 2015, 24, 259-266.	0.9	24
30	Is maternal plasma DNA testing impacting serum-based screening for aneuploidy in the United States?. <i>Genetics in Medicine</i> , 2015, 17, 897-900.	1.1	4
31	Vitamin D Supplementation Decreases TGF- β 1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4307-4314.	1.8	77
32	Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass. <i>Gynecologic Oncology</i> , 2015, 139, 248-252.	0.6	10
33	Evidence of Placental Hypoxia in Maternal Sleep Disordered Breathing. <i>Pediatric and Developmental Pathology</i> , 2015, 18, 380-386.	0.5	66
34	Lethal Hypoplasia and Developmental Anomalies of the Lungs in a Newborn with Intrauterine Adrenal Hemorrhage and Cerebral Infarcts: A Proposed Pulmonary Disruption Sequence. <i>Pediatric and Developmental Pathology</i> , 2014, 17, 374-381.	0.5	6
35	Multisite evaluation of a monoclonal IMMULITE erythropoietin immunoassay. <i>Clinical Biochemistry</i> , 2014, 47, 216-219.	0.8	1
36	Maternal plasma DNA testing for aneuploidy in pregnancies achieved by assisted reproductive technologies. <i>Genetics in Medicine</i> , 2014, 16, 419-422.	1.1	12

#	ARTICLE	IF	CITATIONS
37	Down syndrome screening: Suitability of a WHO 5 standardized total hCG assay. <i>Clinical Biochemistry</i> , 2014, 47, 629-631.	0.8	9
38	Maternal Plasma DNA Testing: Experience of Women Counseled at a Prenatal Diagnosis Center. <i>Genetic Testing and Molecular Biomarkers</i> , 2014, 18, 665-669.	0.3	2
39	Use of first or second trimester serum markers, or both, to predict preeclampsia. <i>Pregnancy Hypertension</i> , 2014, 4, 271-278.	0.6	14
40	Implications of High Free Thyroxine (FT4) Concentrations in Euthyroid Pregnancies: The FaSTER Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2038-2044.	1.8	38
41	HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. <i>Scientific Reports</i> , 2014, 4, 3574.	1.6	79
42	Impact of Adjusting for the Reciprocal Relationship Between Maternal Weight and Free Thyroxine During Early Pregnancy. <i>Thyroid</i> , 2013, 23, 225-230.	2.4	25
43	The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. <i>Prenatal Diagnosis</i> , 2013, 33, 667-674.	1.1	310
44	Feasibility of Using Plasma Rather Than Serum in First and Second Trimester Multiple Marker Down's Syndrome Screening. <i>Journal of Medical Screening</i> , 2012, 19, 164-170.	1.1	1
45	DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. <i>Genetics in Medicine</i> , 2012, 14, 296-305.	1.1	471
46	Expression of transcription factors controlling alpha inhibin gene expression in placental tissues from pregnancies affected by fetal Down syndrome. <i>Prenatal Diagnosis</i> , 2012, 32, 302-305.	1.1	4
47	DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations. <i>Prenatal Diagnosis</i> , 2012, 32, 730-734.	1.1	153
48	Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, 349.e1-349.e7.	0.7	117
49	Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, 351.e1-351.e8.	0.7	116
50	DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. <i>Genetics in Medicine</i> , 2011, 13, 913-920.	1.1	809
51	Utility of Tumor Marker HE4 to Predict Depth of Myometrial Invasion in Endometrioid Adenocarcinoma of the Uterus. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1.	1.2	58
52	The relationship between PTH and 25-hydroxy vitamin D early in pregnancy. <i>Clinical Endocrinology</i> , 2011, 75, 309-314.	1.2	35
53	Use of in-cycle antimüllerian hormone levels to predict cycle outcome. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 223.e1-223.e5.	0.7	19
54	Adjustment of maternal serum alpha-fetoprotein levels in women with pregestational diabetes. <i>Prenatal Diagnosis</i> , 2011, 31, 282-285.	1.1	7

#	ARTICLE	IF	CITATIONS
55	Impact of smoking on maternal serum markers and prenatal screening in the first and second trimesters. <i>Prenatal Diagnosis</i> , 2011, 31, 583-588.	1.1	24
56	Cardiovascular disease risk factors and DNA methylation at the LINE-1 repeat region in peripheral blood from Samoan Islanders. <i>Epigenetics</i> , 2011, 6, 1257-1264.	1.3	95
57	Thyroperoxidase and Thyroglobulin Antibodies in Early Pregnancy and Placental Abruption. <i>Obstetrics and Gynecology</i> , 2011, 117, 287-292.	1.2	17
58	Relationships Between Cell-Free DNA and Serum Analytes in the First and Second Trimesters of Pregnancy. <i>Obstetrics and Gynecology</i> , 2010, 116, 673-678.	1.2	9
59	Examination of the pregnancy-associated plasma protein-A assay on the Beckman Coulter Access [®] platform: suitability for use in first trimester Down's syndrome screening. <i>Journal of Medical Screening</i> , 2010, 17, 109-113.	1.1	5
60	Thyroperoxidase and Thyroglobulin Antibodies in Early Pregnancy and Preterm Delivery. <i>Obstetrics and Gynecology</i> , 2010, 116, 58-62.	1.2	65
61	Adjustment of Serum Markers in First Trimester Screening. <i>Journal of Medical Screening</i> , 2009, 16, 102-103.	1.1	10
62	Early onset preeclampsia and second trimester serum markers. <i>Prenatal Diagnosis</i> , 2009, 29, 1109-1117.	1.1	14
63	Variations in serum α_1 -antitrypsin inhibiting substance between white, black, and Hispanic women. <i>Fertility and Sterility</i> , 2009, 92, 1674-1678.	0.5	131
64	Plasma brain-derived neurotrophic factor in women after bariatric surgery: a pilot study. <i>Fertility and Sterility</i> , 2009, 91, 1544-1548.	0.5	26
65	Inhibin B reference data for fertile and infertile men in Northeast America. <i>Fertility and Sterility</i> , 2009, 92, 1920-1923.	0.5	24
66	Smoking in pregnancy is associated with increased total maternal serum cell-free DNA levels. <i>Prenatal Diagnosis</i> , 2008, 28, 186-190.	1.1	15
67	First- and second-trimester thyroid hormone reference data in pregnant women: a FaSTER (First- and Tj ETQq1 1 0.784314 rgBT /Ove Obstetrics and Gynecology, 2008, 199, 62.e1-62.e6.	0.7	99
68	Sequential first- and second-trimester TSH, free thyroxine, and thyroid antibody measurements in women with known hypothyroidism: a FaSTER trial study. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, 129.e1-129.e6.	0.7	33
69	The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. <i>Gynecologic Oncology</i> , 2008, 108, 402-408.	0.6	594
70	Comparison of serum and plasma measurements of α_1 -antitrypsin inhibiting substance. <i>Fertility and Sterility</i> , 2008, 89, 1836-1837.	0.5	6
71	Quality assessment of routine nuchal translucency measurements: a North American laboratory perspective. <i>Genetics in Medicine</i> , 2008, 10, 131-138.	1.1	47
72	Variability in Thyroid-Stimulating Hormone Suppression by Human Chronic Gonadotropin during Early Pregnancy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3341-3347.	1.8	87

#	ARTICLE	IF	CITATIONS
73	Maternal Thyroid Hypofunction and Pregnancy Outcome. <i>Obstetrics and Gynecology</i> , 2008, 112, 85-92.	1.2	394
74	Very High Inhibin A Concentration Attributed to Heterophilic Antibody Interference. <i>Clinical Chemistry</i> , 2007, 53, 800-801.	1.5	8
75	Comparison of Serum Markers in First-Trimester Down Syndrome Screening. <i>Obstetrics and Gynecology</i> , 2007, 109, 783.	1.2	1
76	Biologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women. <i>Fertility and Sterility</i> , 2007, 88, 1645-1652.	0.5	45
77	Proteomic Analysis of Maternal Serum in Down Syndrome: Identification of Novel Protein Biomarkers. <i>Journal of Proteome Research</i> , 2007, 6, 1245-1257.	1.8	85
78	Activin Subunit and Receptor Expression in Normal and Cleft Human Fetal Palate Tissues. <i>Pediatric and Developmental Pathology</i> , 2007, 10, 436-445.	0.5	3
79	Comparison of Serum Markers in First-Trimester Down Syndrome Screening. <i>Obstetrics and Gynecology</i> , 2006, 108, 1192-1199.	1.2	44
80	Stability of first- and second-trimester serum markers after storage and shipment. <i>Prenatal Diagnosis</i> , 2006, 26, 17-21.	1.1	21
81	Total activin A in maternal blood as a marker of preterm delivery in low-risk asymptomatic patients. <i>Prenatal Diagnosis</i> , 2006, 26, 277-281.	1.1	10
82	Second-Trimester Maternal Serum Markers in Twin Pregnancy with Complete Mole: Report of 2 Cases. <i>Pediatric and Developmental Pathology</i> , 2005, 8, 230-234.	0.5	11
83	Apparently low maternal serum inhibin A levels in second-trimester screening. <i>Prenatal Diagnosis</i> , 2005, 25, 967-968.	1.1	2
84	Follicular Arrest in Polycystic Ovary Syndrome Is Associated with Deficient Inhibin A and B Biosynthesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5582-5587.	1.8	78
85	Cell-free fetal DNA levels in pregnancies conceived by IVF. <i>Human Reproduction</i> , 2005, 20, 3152-3156.	0.4	30
86	First-Trimester or Second-Trimester Screening, or Both, for Down's Syndrome. <i>New England Journal of Medicine</i> , 2005, 353, 2001-2011.	13.9	1,044
87	Clinical Application of Inhibin A Measurement: Prenatal Serum Screening for Down Syndrome. <i>Seminars in Reproductive Medicine</i> , 2004, 22, 235-242.	0.5	12
88	Effect of folic acid fortification on prevalence of neural tube defects in Rhode Island. <i>Journal of Medical Screening</i> , 2004, 11, 106-107.	1.1	4
89	Inverse Correlation Between Maternal Weight and Second Trimester Circulating Cell-Free Fetal DNA Levels. <i>Obstetrics and Gynecology</i> , 2004, 104, 545-550.	1.2	46
90	Placenta growth factor levels in second-trimester maternal serum in Down syndrome pregnancy and in the prediction of preeclampsia. <i>Prenatal Diagnosis</i> , 2004, 24, 876-880.	1.1	14

#	ARTICLE	IF	CITATIONS
91	Ovarian brain-derived neurotrophic factor is present in follicular fluid from normally cycling women. <i>Fertility and Sterility</i> , 2003, 79, 451-452.	0.5	43
92	Evaluation of Cell-free Fetal DNA as a Second-Trimester Maternal Serum Marker of Down Syndrome Pregnancy. <i>Clinical Chemistry</i> , 2003, 49, 239-242.	1.5	79
93	Concentrations of serum total activin A and inhibin A in preterm and term labor patients: a cross-sectional study. <i>Journal of the Society for Gynecologic Investigation</i> , 2003, 10, 231-236.	1.9	14
94	Down syndrome and cell-free fetal DNA in archived maternal serum. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 187, 1217-1221.	0.7	84
95	Mechanism of increased maternal serum total activin a and inhibin a in preeclampsia. <i>Journal of the Society for Gynecologic Investigation</i> , 2002, 9, 308-312.	1.9	34
96	Physiology and pathophysiology of inhibin A and activin A in human pregnancy. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2000, 7, 337-344.	0.6	1
97	Progesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies. <i>Obstetrics and Gynecology</i> , 2000, 95, 227-231.	1.2	30
98	Analysis of follicular fluid hormone concentrations and granulosa cell mRNA levels for the inhibin-activin-follistatin system: relation to oocyte and embryo characteristics. <i>Fertility and Sterility</i> , 2000, 74, 348-355.	0.5	34
99	Inhibin B response to EFORT is associated with the outcome of oocyte retrieval in the subsequent in vitro fertilization cycle. <i>Fertility and Sterility</i> , 2000, 74, 1114-1117.	0.5	55
100	Comparison of maternal serum total activin A and inhibin A in normal, preeclamptic, and nonproteinuric gestationally hypertensive pregnancies. <i>American Journal of Obstetrics and Gynecology</i> , 1999, 180, 1131-1137.	0.7	93
101	Imbalanced Expression of Inhibin and Activin Subunits in Primary Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1998, 69, 23-31.	0.6	67
102	Increased concentrations of prostate-specific antigen in maternal serum from pregnancies affected by fetal Down syndrome. <i>Clinical Chemistry</i> , 1998, 44, 205-208.	1.5	13
103	Characterization of Intrafollicular Steroid Hormones, Inhibin, and Follistatin in Women with and without Polycystic Ovarian Syndrome Following Gonadotropin Hyperstimulation ¹ . <i>Biology of Reproduction</i> , 1997, 57, 1211-1216.	1.2	38
104	Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. <i>Fertility and Sterility</i> , 1997, 67, 110-114.	0.5	306